Status:
UNKNOWN
Efficacy Study of Chemotherapy Followed by Radiation Therapy to Treat Endometrial Cancer
Lead Sponsor:
Asan Medical Center
Collaborating Sponsors:
Boryung Pharmaceutical Co., Ltd
Conditions:
Endometrial Cancer
Eligibility:
FEMALE
20-75 years
Phase:
PHASE2
Brief Summary
Previous some studies suggested the addition of chemotherapy to radiation therapy after surgery may have survival benefit in patients with high risk endometrial cancer. In addition, docetaxel plus cis...
Eligibility Criteria
Inclusion
- One of following high risk groups Stage III after staging operation Stage II (Type I hysterectomy + BSO + LND) Stage I + two of \[Grade III, LVSI+, Mm\>1/2\] Clear cell or serous carcinoma: stage IB-II
- Age: 20-75
- ECOG PS: 0-2
- Adequate organ function BM: WBC ≥ 3,000/mm3, ANC≥1,500/mm3, Plt≥100X103/mm3, Hb≥10.0 g/dl Kidney: Creatinine \<1.25 × UNL이고, GFR ≥ 60 Liver: AST, ALT\< 3×UNL, T- bil\<1.5 mg/ mm3
- Informed Consent
Exclusion
- Previous chemotherapy or pelvic RT
- Hormone therapy within 4 weeks
- Other malignant disease
- Uncontrolled medical disease
- Infection requiring antibiotics
- Symptomatic CHF, RF, Angina, Arrhythmia, etc.
- Neurosis or psychosis
- Etc.
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT01461746
Start Date
October 1 2011
End Date
December 1 2017
Last Update
May 31 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 138-736